Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

At the 2015 ASCO Annual Meeting, we witnessed an extraordinary explosion into the general oncology consciousness of the Programmed Death-1: Programmed Death Ligand-1 axis and drugs that target that interaction.

Jason J. Luke, MD, FACP, discusses the stark change in funding priorities by the United States for biomedical research, and the consequences of that.

With the proliferation of agents for cancer over the past few years, including both targeted and immunotherapies, the number of clinical questions surround- ing optimal sequencing and combinations approaches infinity.

Over the past decade drug development in cancer has shifted to an increasingly gene target–based approach.